Novosibirsk · Russian-qualified counsel Recognised by Pravo-300 · Best Lawyers · Kommersant
Asset Tracing & Recovery

Unwinding shell company structures with Russian elements in the pharmaceuticals sector: what in-house counsel need to know

Elizaveta Razina · July 2026 · 11 min read

Foreign creditors facing Russian pharma shell structures need a clear recovery route. This guide sets out the procedural steps. Make an enquiry.

When a pharmaceutical creditor — a foreign manufacturer, licensor, or institutional investor — discovers that its Russian counterparty has embedded assets within a layered shell structure, the path to recovery narrows quickly. Russian pharmaceutical distribution chains frequently involve multiple intermediate entities: a Russian importer registered to hold the import licence, a separate warehousing company holding physical stock, a marketing entity holding the trade mark sub-licence, and one or more offshore holding vehicles above them. Each layer serves a legitimate commercial function and an equally functional asset-protection purpose. For in-house counsel instructed to recover value from this structure, the practical question is not whether the layers can be unwound, but in what sequence, through which forum, and before which assets have been dissipated further. This guide sets out that sequence under Russian law as it currently applies to pharmaceutical sector structures.

What to prepare before initiating proceedings

Before any formal step is taken, the following documentary base should be assembled. Missing even one item routinely causes delays of three to six months in Russian proceedings.

If you are assembling this documentary base under time pressure — make an enquiry: info@vetrovpartners.com |

Step 1 — Map the corporate structure before selecting a forum

The first task is to construct a verified map of the Russian elements of the pharmaceutical group. This is not a background-check exercise — it is a jurisdictional and sequencing exercise that determines which court or authority has competence over which entity and which asset class.

In pharmaceutical sector structures, the legally significant assets are distributed across distinct registration regimes. Import licences and product marketing authorisations (государственная регистрация лекарственных средств) are held by the legal entity that is named on the certificate. They are non-transferable in the ordinary sense: a transfer of ownership of the licence-holding entity does not automatically transfer the licence to a new owner; regulatory approval by the Ministry of Health (Minzdrav) is required. This is material for a creditor: if the only valuable asset of the Russian operating entity is its regulatory position — the licences that allow it to import and distribute pharmaceutical products in Russia and, where relevant, across EAEU member states — then pledging or enforcing against that regulatory position requires regulatory engagement, not just court orders.

The mapping exercise should identify: (a) which entity holds the operating assets (licences, stock, receivables), (b) which entity holds the immovable or registrable property (real estate, equipment, vehicles), (c) which entity is the counterparty to the creditor's underlying claim, and (d) the ownership chain linking these entities, including any offshore intermediate holding companies. For structures with EAEU elements — for instance, a Belarusian or Kazakh entity holding distribution rights for the same pharmaceutical product — the Russian law analysis must be coordinated with local counsel in the relevant member state, as EAEU regulatory frameworks create cross-border licensing obligations that can affect asset realisation.

For cluster context on how recent Russian legislative changes affect this mapping exercise, see our analysis at Legislative amendment affecting unwinding shell company structures.

Step 2 — Identify and apply for interim measures in the Russian arbitrazh court

Once the corporate map is established, interim measures (обеспечительные меры) must be applied for without delay. Under Russian civil procedure, an application for interim measures can be made at the same time as or immediately following the filing of the main claim. Courts do not require the claimant to prove irreparable harm in the English law sense — the test is less demanding, centring on whether the absence of the measure would render enforcement of any future judgment materially more difficult.

In pharmaceutical sector matters, the assets most commonly subject to interim freezing orders are: bank accounts held by the operating entity, receivables owed by pharmaceutical retailers or distributors under current supply contracts, and warehoused stock where the creditor can demonstrate a specific claim over the goods. Intellectual property assets — trade mark sub-licences, exclusive distribution rights — present a more complex picture. Russian courts will freeze sub-licence agreements as contractual rights, but enforcement against the underlying IP requires separate proceedings and, in the case of trade marks registered with Rospatent, coordination with the IP Court (Суд по интеллектуальным правам).

The interim measures application should be filed in the arbitrazh court at the location of the defendant entity's registered address. Where multiple Russian entities are involved, the creditor must select one as the primary respondent and seek to join the others as co-respondents or co-defendants. Courts in the Siberian and Ural federal districts have shown willingness to consolidate related claims against commonly owned entities where the structural connection is documented — reducing the risk of parallel proceedings producing inconsistent outcomes.

Timing is the controlling variable here. In a recent matter, the firm acted for a European trade creditor in proceedings against a Russian pharmaceutical distributor where the defendant initiated a voluntary restructuring filing within six weeks of the creditor's first formal demand. By that point, interim measures had not yet been applied for. The result was a creditors' queue rather than a direct enforcement sequence, extending the recovery timeline by over eighteen months.

For in-house counsel who are managing a live creditor position in a Russian pharmaceutical structure and have not yet applied for interim measures, the procedural window may be narrowing.

To assess whether interim measures are still available in your matter — make an enquiry: info@vetrovpartners.com |

Step 3 — Challenge intercompany transactions under Russian insolvency legislation

Where the debtor entity has already entered insolvency proceedings, or where the creditor has reason to believe that assets were moved between group entities in anticipation of a claim, the mechanism for reaching those assets shifts. Russian insolvency legislation provides for the challenge of transactions that were concluded in the period preceding the insolvency filing — the relevant look-back windows vary depending on the nature of the transaction, but preferential and undervalue transactions can be challenged over a period of up to three years before the filing date in certain circumstances.

In pharmaceutical sector structures, the transactions most frequently challenged are: intercompany supply agreements under which stock was transferred to a related entity at below-market price; sub-licence assignments that stripped the operating entity of its distribution rights without adequate consideration; and loan repayments made to affiliated offshore entities in the months before insolvency. Each of these requires the creditor to demonstrate not only the transactional terms but also the relational connection between the counterparties — which is precisely why the corporate mapping in Step 1 is the necessary foundation.

The challenge is brought in the insolvency proceedings themselves, by the insolvency administrator (арбитражный управляющий) or, where the administrator is passive or conflicted, by the creditor directly. Foreign creditors are entitled to participate in Russian insolvency proceedings and to file creditor claims, subject to compliance with the claims registration deadline set by the court. Missing that deadline produces a subordinated creditor position — not exclusion, but a materially worse recovery prospect.

For a comparative analysis of how different offshore jurisdictions interact with Russian insolvency procedures in unwinding pharmaceutical shell structures, see Comparative analysis: unwinding shell company structures with offshore elements.

Step 4 — Engage the regulatory dimension

How does Russian pharmaceutical regulation affect creditor recovery?

The recovery analysis for pharmaceutical sector structures cannot be separated from the regulatory framework. A creditor who secures a judgment against the licence-holding entity and seeks to enforce against the licences themselves will find that Russian law treats pharmaceutical product marketing authorisations as administrative permissions attached to a specific legal entity — not as freely assignable property rights in the way that, for example, a trade mark registration is.

The practical consequence is this: a forced sale of the licence-holding entity's shares (where the creditor holds a pledge over the shareholding) may result in the acquirer inheriting the regulatory position, subject to Minzdrav consent for any change of control that triggers a notification requirement. However, a forced sale of the licences themselves, as standalone assets, is not possible under current Russian pharmaceutical regulation without a regulatory transfer procedure that typically takes several months and requires demonstration that the transferee meets applicable GMP and import-compliance standards.

This is a material recovery risk for creditors whose security package is centred on the licence-holding entity's operational assets rather than its shares or real property. The mitigation is to ensure that the security package — or the interim measures application — covers both the shares and the physical assets of the operating entity, so that enforcement can proceed along whichever route the regulatory timeline permits.

EAEU-registered pharmaceutical products add a further dimension: a product registered under the unified EAEU drug registration procedure is valid across all five EAEU member states. If the Russian licence-holding entity also holds EAEU registration certificates, those certificates remain valid even if the Russian entity changes ownership — but the regulatory obligations (pharmacovigilance, post-market surveillance) transfer to the new holder. Creditors acquiring such entities through enforcement should take separate advice on regulatory succession obligations before completing any transfer.

The firm's asset tracing and recovery practice regularly advises foreign creditors on the intersection of enforcement mechanics and regulatory succession in pharmaceutical and life sciences matters before Russian courts and regulatory authorities.

Step 5 — Coordinate enforcement with the Federal Bailiffs' Service

Once a writ of execution (исполнительный лист) has been issued by the arbitrazh court, enforcement passes to the Federal Bailiffs' Service (ФССП). In practice, creditors who engage actively with the enforcement process — filing regular requests for information on the debtor's asset position, requesting the bailiff to query the Federal Tax Service and the Federal Property Management Agency for registered assets — achieve materially better outcomes than creditors who file the writ and wait.

For pharmaceutical sector debtors, the bailiff's queries should specifically target: registered real estate held by the operating or warehousing entity; vehicles registered to any group entity; bank accounts at Russian credit institutions; and any receivables from state procurement contracts (государственные контракты) for pharmaceutical products — a category that is particularly significant in the Russian pharmaceutical market, where state hospital procurement represents a large share of revenue for many distributors.

State procurement receivables are attachable under Russian enforcement procedure. Where a pharmaceutical distributor holds a state contract for supply to regional hospitals or federal medical institutions, the bailiff can attach the payment stream at source by serving notice on the relevant state customer. This is one of the most effective enforcement levers available to creditors in this sector and is frequently underused by foreign creditors unfamiliar with Russian procurement architecture.

Frequently asked questions

Q: How long does the full unwinding process typically take in Russian pharmaceutical sector matters?

A: Timeline varies considerably depending on the number of Russian entities in the structure and whether the debtor entity is already in insolvency proceedings. In straightforward matters — a single Russian operating entity, a clear debt instrument, and assets that are identifiable and not yet transferred — the sequence from interim measures to enforcement of a writ of execution runs between eight and eighteen months in most circuits. Where insolvency proceedings are concurrent, or where transaction challenges are necessary, timelines extend further, commonly to two to three years. The single most significant factor affecting timeline is the speed with which interim measures are applied for: creditors who secure freezing orders before the debtor can reorganise its asset base consistently achieve shorter recovery timelines.

Q: What documents does a foreign creditor need to participate in Russian insolvency proceedings?

A: Foreign creditors must file a certified claim supported by the underlying debt instrument (contract, supply agreement, judgment, or arbitral award) with a certified Russian translation and, where issued in a foreign jurisdiction, an apostille. The claim must be filed within the statutory deadline published in the official court notice — typically thirty days from the date of the notice for standard creditors. Supporting documentation should include any evidence of prior payment demands and the debtor's acknowledgement (if any) of the debt. Foreign creditors are not required to have a Russian registered entity to file a claim, but engaging Russian procedural counsel is strongly advisable to avoid technical grounds for claim rejection.

Q: Can a creditor reach assets held by affiliated entities that are not direct counterparties to the underlying debt?

A: Reaching assets in affiliated entities that are not direct debtors requires either a separate claim against those entities — which in turn requires a legal basis, such as a guarantee, a pledge, a fraudulent transfer claim, or a piercing of the corporate veil under the subsidiary liability (субсидиарная ответственность) provisions of Russian insolvency legislation — or a challenge to intercompany transactions that stripped assets from the primary debtor. Neither route is straightforward, and both require a documented factual basis. Courts do not pierce corporate structures on the basis of economic interconnection alone. The corporate mapping exercise in Step 1 is designed specifically to identify which of these routes is available and which is most likely to succeed given the specific structure.

Practitioner note

This briefing is general information and does not constitute legal advice. For advice on a specific matter, write in confidence to info@vetrovpartners.com.

Facing a matter like this?

Our team advises foreign clients on exactly these questions across Russia and the EAEU region. Initial 30-minute consultation — complimentary.

Make an enquiry